57514-09-7

Basic information

• Product Name: (2,2-DIFLUORO-1-METHYLETHYL)BENZENE
• Synonyms: (2,2-DIFLUORO-1-METHYLETHYL)BENZENE;(1,1-difluoropropan-2-yl)benzene
• CAS NO: 57514-09-7
• Molecular Formula: C₉H₁₀F₂
• Molecular Weight: 156.17
• Mol File: 57514-09-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 159.438 °C at 760 mmHg
• Flash Point: 38.508 °C
• Appearance: /
• Density: 1.036g/cm³
• CAS DataBase Reference: (2,2-DIFLUORO-1-METHYLETHYL)BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: (2,2-DIFLUORO-1-METHYLETHYL)BENZENE(57514-09-7)
• EPA Substance Registry System: (2,2-DIFLUORO-1-METHYLETHYL)BENZENE(57514-09-7)

Safety Data

• Hazardous Substances Data: 57514-09-7(Hazardous Substances Data)

Upstream product

• 873-66-5 1-propenylbenzene 
• 74492-31-2 α-(Chlorodifluoromethyl)styrene 
• 141694-58-8 Trifluoro-methanesulfonic acid 2-phenyl-1-trifluoromethanesulfonyloxy-propyl ester 
• 34713-70-7 2-Phenylpropanal 
• 17173-35-2 (+/-)-1-Chlor-1,1-difluor-2-phenyl-propan-2-ol 
• 345-60-8 α-(difluoromethyl)styrene 
• 395-01-7 2,2-difluoro-1-phenylethanone 

Downstream Products

• 1263283-07-3 C₉H₁₀F₂O₃S 
• 883146-12-1 4-(1,1-difluoropropan-2-yl)benzenesulfonyl chloride 
• 883146-13-2 2-(1,1-difluoropropan-2-yI)benzene-1-sulfonyl chloride 

Relevant articles and documents

Photocatalytic alkene reduction by a B12-TiO2 hybrid catalyst coupled with C-F bond cleavage for: Gem -difluoroolefin synthesis

Photocatalytic syntheses of gem-difluoroolefins were performed using the B12-TiO2 hybrid catalyst during the CC bond reduction of α-trifluoromethyl styrenes with C-F bond cleavage at room temperature under nitrogen. The gem-difluoroolefins were used as synthetic precursors for fluorinated cyclopropanes.

AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5-or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3;R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated Cl-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C 4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1--C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C 3-C4-cycloalkylmethyl, fluorinated C3--C 4-alkenyl, or R1a and R2 together are (CH 2)n with n being 2, 3 or 4, or R1a and R 2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are independently of each other H, C1-C4-alkyl or fluorinated C1-C 4-alkyl or R2a and R2 together are (CH 2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.